Literature DB >> 8091851

Human live anthrax vaccine in the former USSR.

E N Shlyakhov1, E Rubinstein.   

Abstract

The history of the development and use of the Soviet live spore human anthrax vaccine is described. Results of mass field trials on this vaccine following administration by scarification, by subcutaneous injection route or by aerosol exposure are presented. For the immunological assessment of these vaccinations a skin test with an original product 'Anthraxin' was used.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8091851     DOI： 10.1016/0264-410x(94)90223-2

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  28 in total

Review 1.  Bacterial infectious disease control by vaccine development.

Authors:  Roy Curtiss
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax.

Authors:  E Shlyakhov; E Rubinstein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

3.  Bacillus cereus G9241 makes anthrax toxin and capsule like highly virulent B. anthracis Ames but behaves like attenuated toxigenic nonencapsulated B. anthracis Sterne in rabbits and mice.

Authors:  Melissa K Wilson; James M Vergis; Farhang Alem; John R Palmer; Andrea M Keane-Myers; Trupti N Brahmbhatt; Christy L Ventura; Alison D O'Brien
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

Review 4.  New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.

Authors:  J M Beierlein; A C Anderson
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Diversity of Bacillus anthracis strains in Georgia and of vaccine strains from the former Soviet Union.

Authors:  Maya Merabishvili; Merab Natidze; Sergo Rigvava; Lorenzo Brusetti; Noura Raddadi; Sara Borin; Nina Chanishvili; Marina Tediashvili; Richard Sharp; Maurizio Barbeschi; Paolo Visca; Daniele Daffonchio
Journal:  Appl Environ Microbiol       Date:  2006-08       Impact factor: 4.792

6.  Inhibition of CFTR Cl- channel function caused by enzymatic hydrolysis of sphingomyelin.

Authors:  Yajamana Ramu; Yanping Xu; Zhe Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-30       Impact factor: 11.205

7.  Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.

Authors:  S Cohen; I Mendelson; Z Altboum; D Kobiler; E Elhanany; T Bino; M Leitner; I Inbar; H Rosenberg; Y Gozes; R Barak; M Fisher; C Kronman; B Velan; A Shafferman
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

8.  Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis.

Authors:  Vito G Delvecchio; Joseph P Connolly; Timothy G Alefantis; Alexander Walz; Marian A Quan; Guy Patra; John M Ashton; Jessica T Whittington; Ryan D Chafin; Xudong Liang; Paul Grewal; Akbar S Khan; Cesar V Mujer
Journal:  Appl Environ Microbiol       Date:  2006-09       Impact factor: 4.792

9.  Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.

Authors:  Angelo Scorpio; Donald J Chabot; William A Day; David K O'brien; Nicholas J Vietri; Yoshifumi Itoh; Mansour Mohamadzadeh; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

Review 10.  Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.

Authors:  Charles E Binkley; Sandro Cinti; Diane M Simeone; Lisa M Colletti
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.